NAFLD / MASLD Diagnostic Algorithm, Step by Step

Why the Rename Matters for Diagnosis

The 2023 multi-society consensus replaced "NAFLD" with "MASLD" to reflect the condition's metabolic roots rather than what it is not. That shift is more than cosmetic. The new framework requires clinicians to confirm at least one of five cardiometabolic criteria, overweight/obesity, prediabetes or type 2 diabetes, hypertension, elevated triglycerides, or low HDL-cholesterol, before assigning the diagnosis. Patients who have hepatic steatosis without any of those criteria now fall into a separate category called cryptogenic steatotic liver disease [1].

The Five Cardiometabolic Criteria

A patient must meet hepatic steatosis plus at least one of the following [1, 2]:

• BMI ≥25 kg/m² (or ≥23 kg/m² in Asian populations)
• Fasting glucose ≥100 mg/dL, HbA1c ≥5.7%, or a prior diagnosis of type 2 diabetes
• Blood pressure ≥130/85 mmHg or antihypertensive therapy
• Triglycerides ≥150 mg/dL or lipid-lowering therapy
• HDL-cholesterol <40 mg/dL (men) or <50 mg/dL (women)

Meeting this checklist takes under two minutes in clinic. Most patients referred for elevated liver enzymes or incidental hepatic steatosis on imaging will qualify immediately.

Who Carries the Diagnosis

MASLD affects an estimated 25 to 30% of U.S. Adults, making it the most common chronic liver disease in high-income countries [3]. Among patients with type 2 diabetes, prevalence rises to 55 to 70%. Progression to metabolic-associated steatohepatitis (MASH, formerly NASH) occurs in roughly 20% of MASLD patients, and approximately 20% of those with MASH will develop advanced fibrosis within a decade [4].

Step 1, Identify Who Needs a Workup

Not every person with a high BMI or elevated ALT needs an imaging study today. The algorithm starts with risk stratification, not reflexive testing.

Indications for Initiating the Diagnostic Pathway

Order a workup when any of the following are present [2, 5]:

• Persistently elevated ALT or AST (>upper limit of normal on two occasions at least six months apart) with no clear alternative cause
• Incidental hepatic steatosis reported on abdominal ultrasound, CT, or MRI done for another reason
• Type 2 diabetes, regardless of liver enzyme levels
• Metabolic syndrome (three or more of the cardiometabolic criteria above)
• Family history of cirrhosis or hepatocellular carcinoma

The 2023 AASLD Practice Guidance states: "All patients with metabolic risk factors and incidentally discovered hepatic steatosis should undergo evaluation to determine the stage of liver disease" [2].

Excluding Competing Diagnoses First

Before confirming MASLD, rule out secondary causes of hepatic steatosis. Key conditions to exclude include [2, 6]:

• Significant alcohol use (defined as >21 drinks/week in men, >14 drinks/week in women, if both metabolic risk and alcohol use are present, the designation is MetALD rather than MASLD)
• Hepatitis B and C virus infection
• Autoimmune hepatitis, primary biliary cholangitis
• Wilson disease, hemochromatosis
• Medications known to cause steatosis (amiodarone, methotrexate, tamoxifen, corticosteroids, valproate)

A standard hepatic panel including HBsAg, anti-HCV, ANA, anti-SMA, serum ceruloplasmin, and transferrin saturation covers most competing diagnoses and costs far less than a biopsy.

Step 2, Confirm Hepatic Steatosis

Once competing diagnoses are excluded and at least one cardiometabolic criterion is met, the next step is imaging to confirm steatosis.

Ultrasound as the Entry-Point Test

Liver ultrasound is recommended as the first imaging modality. It detects steatosis with a sensitivity of 60 to 94% and specificity of 88 to 95% when hepatic fat exceeds 20 to 30% [7]. It is widely available, inexpensive, and free of ionizing radiation. The limitation is that it becomes unreliable in severe obesity (BMI >40) and cannot quantify steatosis grade.

A report of "echogenic liver" or "increased hepatic echogenicity" on an ultrasound ordered for another reason is sufficient to trigger the MASLD pathway without repeating the test.

MRI-Based Fat Quantification

Magnetic resonance imaging proton density fat fraction (MRI-PDFF) quantifies hepatic fat with high accuracy (correlation r >0.99 vs. Histology) and detects steatosis when fat content exceeds 5% [8]. An MRI-PDFF ≥5% confirms the imaging criterion for MASLD. This modality is preferred when ultrasound is technically limited, when precise baseline fat quantification is needed for a clinical trial, or when confirming response to pharmacotherapy.

Controlled attenuation parameter (CAP) on FibroScan is an alternative. CAP scores above 248 dB/m correlate with steatosis grade S1 or higher, though operator experience and BMI affect accuracy [9].

When Imaging Alone Suffices

A patient with ultrasound-confirmed steatosis, at least one cardiometabolic criterion, and no elevated enzymes or risk factors for advanced fibrosis does not necessarily need further testing at that visit. Step 3 (fibrosis staging) still applies, but can be conducted with a non-invasive blood test the same day.

Step 3, Stage Fibrosis Without a Biopsy

Fibrosis stage, not the presence of steatosis alone, determines prognosis and drives treatment decisions. Stage F0, F1 carries a low risk of liver-related death; F3, F4 (advanced fibrosis/cirrhosis) carries a 10-year liver-related mortality risk exceeding 10% [4]. Non-invasive tests (NITs) allow accurate staging in most patients without biopsy.

FIB-4 Index, The Primary Screen

The FIB-4 index is the recommended first-line NIT in MASLD guidelines from AASLD, AACE, and the European Association for the Study of the Liver (EASL) [2, 5, 10]. The formula uses age, AST, ALT, and platelet count, all available from a routine CBC and metabolic panel:

FIB-4 = (Age × AST) ÷ (Platelets × √ALT)

Interpretation thresholds [2]:

| FIB-4 Score | Interpretation | Recommended Action | |---|---|---| | <1.30 | Low probability of advanced fibrosis | Reassess every 1 to 2 years | | 1.30 to 2.67 | Indeterminate | Add liver stiffness measurement (LSM) | | ≥2.67 | High probability of advanced fibrosis | Refer to hepatology; consider biopsy |

In patients aged >65, FIB-4 thresholds shift upward (use 2.0 as the low cutoff) because AST and platelet values change with age independently of fibrosis [2].

Elastography for the Indeterminate Zone

Transient elastography (FibroScan) measures liver stiffness in kilopascals (kPa). For MASLD [9, 10]:

• LSM <8 kPa: advanced fibrosis unlikely
• LSM 8 to 12 kPa: indeterminate, add ELF score or VCTE with XL probe in obesity
• LSM >12 kPa: advanced fibrosis likely; hepatology referral warranted

Point shear-wave elastography (pSWE) and MR elastography (MRE) are alternatives when FibroScan is technically limited. MRE shows the highest diagnostic accuracy (AUROC 0.86 to 0.94 for advanced fibrosis) but is costly and less accessible [8].

Enhanced Liver Fibrosis (ELF) Score

The ELF panel (hyaluronic acid, PIIINP, TIMP-1) is a serum fibrosis marker with an AUROC of 0.90 for detecting F3, F4 in MASLD [11]. An ELF score >9.8 indicates significant fibrosis. It is particularly useful when elastography is unavailable or technically inadequate. NICE guidance in the UK recommends ELF as a second-line NIT following FIB-4.

When Liver Biopsy Remains Necessary

Biopsy is not the default. Reserve it for cases where [2]:

• NITs give discordant results and treatment decisions depend on accurate staging
• Competing diagnoses (autoimmune hepatitis, overlap syndrome) cannot be excluded serologically
• A patient is being evaluated for resmetirom therapy and F2, F3 staging confirmation is needed before prescribing

Biopsy samples at least 20 mm of liver tissue. The NAFLD Activity Score (NAS) grades steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocyte ballooning (0 to 2); a NAS of 5 or higher correlates with MASH [12].

Step 4, Direct Treatment Based on Stage

Diagnosis without a treatment plan wastes the workup. The treatment pathway branches at two decision points: fibrosis stage and the presence of MASH histology.

Lifestyle Modification, The Foundation at Every Stage

Weight loss of 3 to 5% reduces hepatic fat; 7 to 10% improves lobular inflammation; 10% or more resolves MASH in approximately 50% of patients and reverses fibrosis in up to 40% [13]. The AASLD recommends caloric restriction plus moderate-intensity aerobic exercise for at least 150 minutes per week as first-line therapy for all MASLD patients regardless of stage [2].

Specific dietary patterns with trial evidence include [13, 14]:

• Mediterranean diet (reduces hepatic fat by 27 to 39% in 6-month trials)
• Low-carbohydrate diets (reduce hepatic fat faster short-term but long-term adherence is lower)
• Avoidance of fructose-sweetened beverages (each additional daily serving correlates with a 19% higher odds of MASH progression)

Pharmacotherapy, Approved and Emerging

Resmetirom (Rezdiffra) received FDA approval on March 14, 2024, making it the first drug approved specifically for MASH with liver fibrosis. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg daily achieved MASH resolution without worsening of fibrosis in 29.9% of patients vs. 9.7% placebo at 52 weeks (P<0.001), and a one-stage or greater fibrosis improvement in 24.2% vs. 14.2% placebo [15]. It is indicated for adults with MASH and moderate-to-advanced fibrosis (F2, F3 on biopsy).

GLP-1 receptor agonists are not yet FDA-approved specifically for MASH but carry substantial supporting evidence. In the ESSENCE phase 3 trial of semaglutide 2.4 mg weekly (N=800), 59% of patients in the semaglutide arm achieved MASH resolution vs. 17% in the placebo arm; fibrosis improvement occurred in 37% vs. 22% [16]. Regulatory submission is anticipated in 2025.

Tirzepatide (GLP-1/GIP dual agonist) showed dose-dependent hepatic fat reduction of 54 to 74% by MRI-PDFF in the SURPASS-3 MRI substudy compared to insulin degludec [17]. Phase 3 MASH data (SURMOUNT-NASH) are expected in 2025 to 2026.

Pioglitazone (thiazolidinedione, off-label for MASH) reduces hepatic steatosis and inflammation and is recommended by AASLD for MASH patients with prediabetes or type 2 diabetes who cannot access newer agents [2]. The PIVENS trial showed histologic improvement in 34% of pioglitazone-treated patients vs. 19% placebo [18].

Vitamin E (800 IU/day) is an option for non-diabetic MASH patients on the basis of the same PIVENS trial, though long-term safety concerns (increased all-cause mortality at doses >400 IU/day in other meta-analyses) limit its use [18, 19].

Managing Comorbidities as Part of MASLD Care

The American Diabetes Association's 2024 Standards of Care call for screening patients with type 2 diabetes for significant liver fibrosis using FIB-4 at least once, given the 55 to 70% MASLD prevalence in that population [20]. Treating metabolic comorbidities directly improves liver outcomes:

• Statin use does not worsen MASLD and likely reduces liver-related events, statins are not contraindicated in MASLD, including compensated cirrhosis [2]
• SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce hepatic fat by 2 to 3 percentage points by MRI-PDFF and show early fibrosis signals in phase 2 trials [21]
• Blood pressure control to <130/80 mmHg reduces portal hypertension progression in patients with compensated cirrhosis

When to Refer and to Whom

Refer to hepatology when [2, 5]:

• FIB-4 ≥2.67 or LSM >12 kPa on any NIT
• Platelet count <150,000/µL (possible portal hypertension)
• Suspected cirrhosis (splenomegaly, varices, thrombocytopenia cluster)
• Consideration for resmetirom therapy requiring biopsy confirmation
• Evaluation for liver transplantation (MELD score ≥15 or hepatic decompensation)

Refer to endocrinology when MASLD coexists with poorly controlled type 2 diabetes, obesity requiring bariatric evaluation, or thyroid disease (hypothyroidism amplifies hepatic steatosis via reduced mitochondrial fatty-acid oxidation) [5].

Monitoring After Diagnosis

Ongoing surveillance depends on fibrosis stage and treatment response. The AASLD recommends [2]:

• F0, F1, FIB-4 <1.30: repeat FIB-4 every 1 to 2 years; liver ultrasound every 2 years
• F2, F3 confirmed: liver ultrasound plus AFP every 6 months for HCC surveillance; repeat elastography every 12 months to assess treatment response
• F4 (cirrhosis): upper endoscopy to screen for varices; liver ultrasound plus AFP every 6 months; discuss transplant listing if decompensation occurs

Patients receiving resmetirom should have LDL-cholesterol monitored at baseline and at 4 weeks, since resmetirom modestly increases LDL (mean +16 mg/dL in MAESTRO-NASH) through its thyromimetic mechanism [15].